**Meet the editor**

Dr. Andrew B. Lemmey, BSc (Hons), MA, PhD, is a clinical exercise physiologist in the School of Sport, Health and Exercise Sciences at Bangor University in the UK He has a 14 year background in leading groundbreaking research into restoring physical function and attenuating disabilities in patients with rheumatoid arthritis (RA). His expertise in this field was recognized by the Ameri-

can College of Sports Medicine, who invited him to author the chapter on arthritis in their influential text "Clinical Exercise Physiology (3rd Ed.)" (Human Kinetics). Dr. Lemmey has over 50 peer-reviewed publications, is a regular speaker at international conferences, and is a member of the British Society for Rheumatology. After gaining his PhD from the University of Adelaide, Dr. Lemmey was a post-doctoral research fellow at Cambridge and Bristol prior to accepting his current academic post at Bangor.

Contents

**Preface IX** 

**Part 2 Biologics 49** 

**Part 1 DMARDs (Disease Modifying Anti-Rheumatic Drugs) and NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) 1** 

Chapter 2 **Novel Formulation Approaches for Dermal and Transdermal** 

**Delivery of Non-Steroidal Anti-Inflammatory Drugs 25** 

**TNF- Converting Enzyme and Matrix Metalloproteinase-3 in SAPHO Syndrome Synovium - A Rare Case Accompanied by Acrodermatitis Continua of Hallopeau: A Case Report** 

**Management of Rheumatoid Arthritis 3**  Hussein Al-Mossawi and John R. Kirwan

Alper Okyar, Yıldız Özsoy and Sevgi Güngör

Chapter 1 **The Clinical Role of Glucocorticoids in the** 

Chapter 3 **The Role of Tocilizumab in the Treatment of Rheumatoid Arthritis 51** 

Sarah K. Brode and Theodore K. Marras

Chapter 5 **Expression of Tumor Necrosis Factor-Alpha (TNF-**

**and Review of Anti-TNF- Therapy 93** 

Koichiro Komiya, Nobuki Terada, Yoshikazu Mizoguchi

Chapter 6 **The Development of Targeted Drug Delivery Systems for Rheumatoid Arthritis Treatment 111** 

Yasuhiko Hirabayashi

Chapter 4 **Mycobacterial Infections Associated with TNF-α Inhibitors 71** 

and Harumoto Yamada

**Part 3 Potential Treatments 109** 

Rebecca A. Bader
